Wells Fargo Downgrades Chinook Therapeutics to Equal-Weight, Raises Price Target to $40
Author: Benzinga Newsdesk | August 01, 2023 05:29am
Wells Fargo analyst Mohit Bansal downgrades Chinook Therapeutics (NASDAQ:KDNY) from Overweight to Equal-Weight and raises the price target from $30 to $40.